Biogen
PulseAugur coverage of Biogen — every cluster mentioning Biogen across labs, papers, and developer communities, ranked by signal.
1 day(s) with sentiment data
-
AI datacenter financing sparks 'debt bomb' fears, but experts say it's not Enron
Experts are raising concerns about a potential "debt bomb" crisis due to large tech companies like Meta and Oracle using off-balance-sheet financing for AI datacenters. These companies form separate entities to build an…
-
Experimental Alzheimer's drug diranersen shows promise targeting tau protein
An experimental Alzheimer's drug, diranersen, has shown promise in slowing cognitive decline by targeting the tau protein, a different approach than current amyloid-focused treatments. While the drug did not meet all it…
-
Autoimmune disease therapies boom amid VC investment; OpenAI targets healthcare
The field of autoimmune disease therapies is experiencing a significant boom, with projected revenues for drugs like AbbVie's Skyrizi expected to reach $33 billion by 2032. This growth is driven by scientific breakthrou…
-
AI model detects hidden multiple sclerosis lesions
A new artificial intelligence model has been developed that can identify previously invisible lesions associated with multiple sclerosis. This AI-driven approach promises to enhance diagnostic capabilities and potential…
-
Glass substrate tech gains market focus amid company R&D updates; Biogen eyes RayThera acquisition
The market is showing increased interest in glass substrate technology, spurred by TSMC's development plan. Several companies, including XingSen Technology, Medi-Tech, Vogue Optoelectronics, and Qibin Group, have announ…
-
Boston Scientific to acquire RayThera for up to $1B; SpaceX overtakes Amazon · 1 source tracked
Boston Scientific is set to acquire RayThera for up to $1 billion, a move aimed at expanding Boston Scientific's pipeline of investigational immunology products. The deal includes an upfront payment and additional payme…
-
New AI method boosts drug property prediction accuracy
Researchers have developed a new pretraining framework called Probabilistic Contrastive Pretraining (PCP) to enhance the prediction of ADME properties crucial for drug discovery. This method combines chemistry-specific …
-
Kordata Dynamics launches neurotech platform for clinical trials
Kordata Dynamics has launched to address a $26 billion market in central nervous system (CNS) therapeutics by integrating neurotechnology into clinical trials. The company, a spinout from BIOS Health, will partner with …
-
GNNs enhanced for drug discovery via ECFP pre-training
Researchers have developed a new strategy to enhance Graph Neural Networks (GNNs) for drug discovery tasks like Quantitative Structure-Activity Relationship (QSAR) studies. This method involves pre-training GNNs to pred…